# Therapy for Advanced NSCLC With EGFR 19delins Mutation

> **NCT07458919** · EARLY_PHASE1 · NOT_YET_RECRUITING · sponsor: **Fuzhou General Hospital** · enrollment: 94 (estimated)

## Conditions studied

- Lung Cancer

## Interventions

- **DRUG:** Icotinib/Gefitinib

## Key facts

- **NCT ID:** NCT07458919
- **Lead sponsor:** Fuzhou General Hospital
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-03-30
- **Primary completion:** 2030-10-30
- **Final completion:** 2030-10-30
- **Target enrollment:** 94 (ESTIMATED)
- **Last updated:** 2026-03-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07458919

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07458919, "Therapy for Advanced NSCLC With EGFR 19delins Mutation". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07458919. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*